Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Adjunctive Cannabis Extract Improves Nausea-Vomiting Prevention in Cancer Patients
2.
World's premier cancer institute faces crippling cuts and chaos
3.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
4.
Exercise could ease symptoms for people with chronic lymphocytic leukemia, support and guidance are lacking: Study
5.
Scientists develop scans that light up aggressive cancer tumors for better treatment
1.
A New Hope: How Procarbazine is Revolutionizing Cancer Treatment
2.
Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion
3.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
4.
Navigating the Complexities of Ph Negative ALL - Part XVI
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation